Summary
In patients with Parkinson' disease and dopaminergic psychosis, clozapine treatment is recommended as the drug is free from extrapyramidal side effects and does not worsen motor symptoms of the underlying disease. The use of clozapine, however, is limited due to its hematotoxic side effects. For treatment of clozapine-induced agranulocytosis, granulocyte colony-stimulating factors (G-CSF) are recommended. We report the case of a 72-years-old male patient with clozapine-induced agranulocytosis and thrombopenia. Neutropenia was successfully treated with G-CSF, but thrombopenia persisted and resolved spontaneously after 14 days. Bone marrow toxicity of clozapine is not restricted to white cell maturation, but may also impair thrombocytopoesis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 329: 162–167
Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D (1996) Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169: 483–488
Durst R, Dorevitch A, Fraenkel Y (1993) Platelet dysfuction associated with clozapine therapy. South Med J 86: 1170–1172
Factor SA, Brown D (1992) Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 7: 125–131
Factor SA, Sanchez-Ramos JR, Weiner WJ (1988) Parkinson's disease: an open trial of pergolide in patients failing bromocriptine therapy. J Neurol Neurosurg Psychiatry 51: 529–533
Factor SA, Brown D, Molho ES, Podskalny GD (1994) Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 44: 544–546
Factor SA, Molho ES, Podskalny GD, Brown D (1995) Parkinson's disease: drug-induced psychiatric states. Adv Neurol 65: 115–138
Gallin JI (1988) Disorders of phagocytic cells. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS (eds) Harrison's principles of internal medicine, 11th edn. McGraw Hill, New York, pp 279–283
Gerson SL (1994) G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 55 [Suppl B]: 1389–142
Goodwin FK (1971) Psychiatric side effects of levodopa in man. JAMA 218: 1915–1929
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442
Klimke A, Klieser E (1995) Das atypische Neuroleptikum Clozapin (Leponex®)-aktueller Kenntnisstand und neuere klinische Aspekte. Fortschr Neurol Psychiatr 63: 173–193
Lieberman JA, Alvir JM (1992) A report on clozapine induced agranulocytosis in the United States. Drug Safety 7'[Suppl 1]: 1–2
Marsden CD, Fahn S (1981) Problems in Parkinson's disease. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, London, pp 1–7
Meltzer HY (1995) Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 3: 64–75
Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995) Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology 12: 39–45
Pfeiffer C, Wagner ML (1994) Clozapine therapy for Parkinson's disease and other movement disorders. Am J Hosp Pharm 51: 3047–3053
Pinter MM, Helscher RJ (1993) Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm [PD Sect] 5: 135–146
Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, Lieberman JA (1992) On the possible mechanisms and predictability of clozapine induced agranulocytosis. Drug Safety 7 [Suppl 1]: 33–44
Rebey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD (1995) Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 45: 432–434
Rondot R, deRecondo J, Coignet A, Ziegler M (1984) Mental disorders in Parkinson's disease after treatment with L-DOPA. Adv Neurol 40: 259–269
Veys PA, Wilkes S, Shah SA, Noyelle R, Hoffbrand AV (1992) Clinical experience of clozapine-induced neutropenia in the UK: laboratory investigation using liquid culture systems and immunofluorocytometry. Durg Safety 7 [Suppl 1]: 26–32
Webster DD (1968) Critical analysis of the disability in Parkinson's disease. Mod Treat 5: 257–282
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rudolf, J., Grond, M., Neveling, M. et al. Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. J. Neural Transmission 104, 1305–1311 (1997). https://doi.org/10.1007/BF01294731
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01294731